+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06333314

Dostarlimab Versus Standard Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic dMMRMSI Non-Colorectal, Non-Endometrial Cancers A Phase 2 Randomized Trial With Crossover

Led by UNICANCER · Updated on 2025-12-02

120

Participants Needed

22

Research Sites

100 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of the immunotherapy drug dostarlimab as a first treatment option for adults with certain advanced or metastatic cancers that have a specific genetic feature called deficient mismatch repair dMMR or microsatellite instability MSI. This study focuses on cancers that are not colorectal or endometrial, including types such as duodenum, small bowel, gastric, pancreatic, ampulla of Vater, adrenocortical carcinoma, neuroendocrine carcinoma, carcinoma of unknown primary, and soft tissue sarcoma. The goal is to compare dostarlimab with the current standard chemotherapy treatments in a phase II clinical trial setting. After signing consent, patients undergo a pre-inclusion period of up to 28 days for eligibility assessments, including confirmation of dMMRMSI status through centralized testing. Participants are then randomly assigned to one of two groups one receives dostarlimab intravenously at 500 mg every 3 weeks for four cycles, then 1000 mg every 6 weeks thereafter the other group receives standard chemotherapy according to current care guidelines. Treatment continues until disease progression, unacceptable side effects, death, or for a maximum of 24 months. Patients initially on chemotherapy who experience disease progression may switch to receive dostarlimab following a washout period. Participants undergo tumor evaluations at the start and regularly during treatmentevery 6 weeks during the first year and every 12 weeks in the second year. After treatment ends, follow-up visits occur every 16 weeks for up to a year. Throughout the study, researchers monitor progression-free survival, response rates, overall survival, circulating tumor DNA levels, side effects, and quality of life using questionnaires. The entire participation may last up to 3 years, including treatment, crossover, and follow-up phases.

CONDITIONS

Brief Title

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Research Team

A

Assia LAMRANI-GHAOUTI

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here